
    
      The drug being observed in this study is called roflumilast. Roflumilast is used to treat
      people who have chronic obstructive pulmonary disease (COPD) associated with chronic
      bronchitis with a history of worsening symptoms. This study looked at side effects and the
      lung function of people who take roflumilast. The study enrolled 2577 patients who were
      already prescribed roflumilast as an add on to bronchiodilator treatment by their healthcare
      provider. This multi-centre trial was conducted in Greece. The overall time to participate in
      this study was up to 6 months. Participants were evaluated during routine appointments with
      their healthcare provider.
    
  